C
Cullinan Therapeutics
Developing a highly diversified portfolio of oncology therapeutics with a unique, cost-efficient business model
About Cullinan Therapeutics
Cullinan Oncology is a biopharmaceutical company focused on developing innovative cancer treatments. The company operates in the oncology market, targeting patients with various types of cancer. Cullinan employs a unique portfolio model, inspired by modern portfolio theory, to manage and develop a diverse range of oncology assets. This approach allows the company to optimize returns while mitigating risks by investing in a broad array of cancer therapies diversified across indications and mechanisms of action.
Cullinan's business model combines internal idea creation with external business development activities to identify and advance promising scientific discoveries. The company maintains a lean infrastructure with nearly zero fixed costs, ensuring capital efficiency. This allows Cullinan to quickly determine the utility of its compounds, making strategic decisions to either progress or terminate programs based on their potential.
Cullinan generates revenue through the development and commercialization of its oncology assets, either independently or through partnerships with other pharmaceutical companies. By advancing therapies from preclinical stages to Phase 2 clinical trials, Cullinan aims to bring transformative cancer treatments to market, improving the standard of care for patients.
Source: Dealroom company dataAt a glance
- Status
- Listed
- Listing
- IPO 2021
- Employees
- 128
- Open positions
- None listed
- Dealroom signal
- 76.2/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotechnology, Oncology, Spinout, Biotech and Pharma, DT and LS, science-based
- Client focus
- B2B
- Investment activity
- 1 company, latest Feb 2019
- Capital deployed
- $0
- Preferred round
- Unknown
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| POST IPO EQUITYOther financing | Apr 2024 | $280M | — | Venrock · Invus · Adage Capital · Rock Springs Capital | ↗ |
| IPOOther financing | Jan 2021 | $287M | $870M | Undisclosed | — |
Growth signals
Latest recorded traffic for Cullinan Therapeutics is 2.3K monthly website visits, up 3733.3% over the last three months. Cullinan Therapeutics's team declined 1.5% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Cullinan Therapeutics in the Cambridge ecosystem
The Cullinan Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A2 investors entered at this stage
- FVF2 Ventures
MPM BioImpact
Series B and later20 investors entered at this stage
Foresite Capital
Cowen Group- SCSchooner Capital
Rock Springs Capital
Nextech Invest
Venrock
OrbiMed
BVF Partners
Eventide Asset Management
Boxer Capital
Logos Capital
The Baupost Group
Invus
Adage Capital
RTW Investments
Avidity Partners
Surveyor Capital
Blue Owl Capital
Braidwell
Paradigm BioCapital
Other known investors3 additional known investors
Cullinan Therapeutics
Helmholtz Association - Helmholtz Gemeinschaft- TVTaiho Ventures
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Cullinan Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Cullinan Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.








